Match!

Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

Published on Mar 1, 2019in Acta Diabetologica2.996
· DOI :10.1007/s00592-018-1253-5
Lorenzo M. Vetrone1
Estimated H-index: 1
(Leicester General Hospital),
Francesco Zaccardi24
Estimated H-index: 24
(Leicester General Hospital)
+ 5 AuthorsKamlesh Khunti66
Estimated H-index: 66
(Leicester General Hospital)
Abstract
Aims To investigate cardiovascular disease and mortality trends in control arm participants of diabetes cardiovascular outcome trials (CVOTs).
  • References (29)
  • Citations (2)
📖 Papers frequently viewed together
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References29
Newest
#1Claire Fitzpatrick (University of Leicester)H-Index: 1
#2Sudesna Chatterjee (University of Leicester)H-Index: 9
Last. Kamlesh Khunti (NIHR: National Institute for Health Research)H-Index: 66
view all 7 authors...
AIMS: Hypoglycaemia is associated with increased cardiovascular risk among individuals with diabetes mellitus. It has been hypothesized that hypoglycaemia may trigger autonomic changes leading to increased cardiac arrhythmia risk. We conducted a systematic review and meta-analysis to explore this association. MATERIALS AND METHODS: Ovid Medline, Embase, Scopus, Web of Science and Cochrane were searched from inception to October 10, 2017. We included studies of adults with diabetes (Type 1 or Typ...
6 CitationsSource
Abstract TOSCA.IT is an institutional, non-industry-supported, head-to-head study comparing long term cardiovascular effects, efficacy and safety of two antidiabetes drugs (pioglitazone vs sulphonylureas) used in combination with metformin in patients with type 2 diabetes mellitus. The study results show that in the absence of clinically evident cardiovascular disease both treatment strategies represent suitable alternatives; however, in consideration of the greater durability of the metabolic e...
1 CitationsSource
#1Francesco Zaccardi (Leicester General Hospital)H-Index: 24
#2Nafeesa N. Dhalwani (Leicester General Hospital)H-Index: 7
Last. Kamlesh Khunti (Leicester General Hospital)H-Index: 66
view all 5 authors...
Aims/hypothesis In the context of increasing prevalence of diabetes in elderly people with multimorbidity, intensive glucose control may increase the risk of severe hypoglycaemia, potentially leading to death. While rising trends of severe hypoglycaemia rates have been reported in some European, North American and Asian countries, the global burden of hypoglycaemia-related mortality is unknown. We aimed to investigate global differences and trends of hypoglycaemia-related mortality.
5 CitationsSource
#1William T. Cefalu (American Diabetes Association)H-Index: 5
#2Sanjay Kaul (Cedars-Sinai Medical Center)H-Index: 27
Last. Matthew C. Riddle (OHSU: Oregon Health & Science University)H-Index: 54
view all 13 authors...
In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-term cardiovascular outcomes trials (CVOTs) for safety. Since 2008, 9 CVOTs have been reported, 13 are under way, and 4 have been terminated. Reassuringly, each of the completed trials demonstrated th...
94 CitationsSource
#1Rebecca K. SimmonsH-Index: 32
#2Simon J. Griffin (University of Cambridge)H-Index: 65
Last. Annelli Sandbæk (AU: Aarhus University)H-Index: 31
view all 4 authors...
Aims/hypothesis There is continuing debate about the net benefits of population screening for type 2 diabetes. We compared the risk of cardiovascular disease (CVD) and mortality among incident cases of type 2 diabetes in a screened group with those in an unscreened group.
19 CitationsSource
#1Aidin Rawshani (University of Gothenburg)H-Index: 6
#2Araz Rawshani (University of Gothenburg)H-Index: 14
Last. Soffia Gudbjörnsdottir (University of Gothenburg)H-Index: 40
view all 10 authors...
BackgroundLong-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes. MethodsWe included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly sele...
196 CitationsSource
#1Merrill Singer (UConn: University of Connecticut)H-Index: 45
#2Nicola Bulled (WPI: Worcester Polytechnic Institute)H-Index: 6
Last. Emily Mendenhall (Georgetown University)H-Index: 16
view all 4 authors...
Summary The syndemics model of health focuses on the biosocial complex, which consists of interacting, co-present, or sequential diseases and the social and environmental factors that promote and enhance the negative effects of disease interaction. This emergent approach to health conception and clinical practice reconfigures conventional historical understanding of diseases as distinct entities in nature, separate from other diseases and independent of the social contexts in which they are foun...
125 CitationsSource
#1Rachel E. Sherman (FDA: Food and Drug Administration)H-Index: 10
#2Steven A. Anderson (FDA: Food and Drug Administration)H-Index: 13
Last. Robert M. Califf (FDA: Food and Drug Administration)H-Index: 8
view all 15 authors...
The FDA is developing guidance on the use of “real-world evidence” — health care information from atypical sources, including electronic health records, billing databases, and product and disease registries — to assess the safety and effectiveness of drugs and devices.
358 CitationsSource
#1Justin B. Echouffo-Tcheugui (Brigham and Women's Hospital)H-Index: 7
#2Haolin Xu (Durham University)H-Index: 8
Last. Gregg C. Fonarow (Ronald Reagan UCLA Medical Center)H-Index: 134
view all 10 authors...
Background The contribution of diabetes to the burden of heart failure (HF) remains largely undescribed. Assessing diabetes temporal trends among US patients hospitalized with HF and their relation with quality measures in real-world practice can help to define this burden. Methods Using data from the Get With the Guidelines–Heart Failure registry, we assessed temporal trends in diabetes prevalence among patients with HF and in subgroups with reduced ejection fraction (HFrEF; EF Results Among 36...
24 CitationsSource
#1Francesco Zaccardi (University of Leicester)H-Index: 24
#2Melanie J. Davies (University of Leicester)H-Index: 82
Last. Kamlesh Khunti (University of Leicester)H-Index: 66
view all 8 authors...
Summary Background Studies in the USA and Canada have reported increasing or stable rates of hospital admissions for hypoglycaemia. Some data from small studies are available for other countries. We aimed to gather information about long-term trends in hospital admission for hypoglycaemia and subsequent outcomes in England to help widen understanding for the global burden of hospitalisation for hypoglycaemia. Methods We collected data for all hospital admissions listing hypoglycaemia as primary ...
35 CitationsSource
Cited By2
Newest
#1Fulvio PomeroH-Index: 16
#2Francesco Dentali (University of Insubria)H-Index: 37
Last. Daniela MastroiacovoH-Index: 5
view all 7 authors...
Direct oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. They have been extensively studied in large trials involving patients affected by the most common cardiovascular diseases. As the presence of diabetes leads to peculiar changes in primary and secondary hemostasis, in this review we highlight the current evidence regarding DOAC use in diabetic patients included in the majority of recently conducted stud...
1 CitationsSource
CONTEXT: Hypoglycemic drugs with proven cardiovascular (CV) benefits are recommended for patients with type 2 diabetes and CV disease. Whether the beneficial effects extend to those at lower risk remains unclear. AIM: We investigated the long-term CV effects of pioglitazone or sulfonylureas (SUs) across the spectrum of pretreatment CV risk. METHODS: Among 2820 participants of the TOSCA.IT trial, four subgroups with different risk of outcome-a composite of all-cause death, nonfatal myocardial inf...
Source